Ovid Therapeutics Inc. (NASDAQ:OVID) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Ovid Therapeutics Inc. (NASDAQ:OVID – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price target […]
More Stories
Trump Designates Fentanyl as Weapon of Mass Destruction
By Darlene McCormick Sanchez President Donald Trump signed an executive order designating fentanyl as a weapon of mass destruction during...
Rob Reiner’s Son Booked for Murder After Director, Wife Found Dead
By Zachary Stieber Nick Reiner has been taken into custody following the death of his parents, Rob and Michele Reiner....
Tomorrow’s Jobs Report to Test the Resilience of the US Labor Market
By Andrew Moran The November jobs report will be released on Dec. 16, revealing the health of the U.S. labor...
US Officials Identify National Guardsmen Killed in ISIS Attack in Syria
By Jack Phillips The two U.S. military members killed over the past weekend in central Syria were Iowa Army National...
Police Detain Person of Interest in Deadly Brown University Shooting
By Jacob Burg A person of interest is in custody over the shooting at Rhode Island’s Brown University on Saturday...
Trump Honors US ‘Miracle on Ice’ Hockey Team in White House Celebration
By Travis Gillmore WASHINGTON—President Donald Trump hosted members of the 1980 U.S. Olympic hockey team at the White House on...